Cellectis
CLLS
#9601
Rank
โ‚ฌ0.10 B
Marketcap
1,06ย โ‚ฌ
Share price
-6.35%
Change (1 day)
-72.25%
Change (1 year)

Earnings for Cellectis (CLLS)

Earnings in 2026 (TTM): -โ‚ฌ56.67 Million

According to Cellectis's latest financial reports the company's current earnings are โ‚ฌ56.57 Million. In 2025 the company made an earning of -โ‚ฌ60.93 Million a decrease over its 2024 earnings that were of -โ‚ฌ32.93 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Cellectis from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -โ‚ฌ56.67 Million-7%
2025 -โ‚ฌ60.93 Million85.03%
2024 -โ‚ฌ32.93 Million-73.42%
2023 -โ‚ฌ0.13 Billion60.8%
2022 -โ‚ฌ77.04 Million-31.26%
2021 -โ‚ฌ0.12 Billion27.21%
2020 -โ‚ฌ88.1 Million-14.62%
2019 -โ‚ฌ0.11 Billion30.34%
2018 -โ‚ฌ79.17 Million-15.03%
2017 -โ‚ฌ93.17 Million62.18%
2016 -โ‚ฌ57.45 Million185.48%
2015 -โ‚ฌ20.13 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.62 B-7,967.20%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-โ‚ฌ0.22 Billion 273.36%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
-โ‚ฌ0.21 Billion 240.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
-โ‚ฌ71.12 Million 20.90%๐Ÿ‡บ๐Ÿ‡ธ USA